Skip to main content
Caplight Logo









Trace Neuroscience

Trace Neuroscience

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.traceneuro.com/

Last Round

Series A

Nov 12, 2024

Total Funding Raised

$101M

Company Overview

Trace Neuroscience is a biopharmaceutical company developing novel genomic therapies to restore UNC13A protein function for the treatment of amyotrophic lateral sclerosis (ALS).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologygenetic medicineRNA therapeuticsneurodegenerative diseasedrug discoveryamyotrophic lateral sclerosisALSRNA regulationantisense oligonucleotidesASObiotech startupclinical-stage biotechtherapeutic platformdrug developmentbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trace Neuroscience Comparables

Compare Trace Neuroscience with similar companies based on industry and business-model similarity.

Trace Neuroscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Harness Therapeutics
86%
AcuraStem
86%
NuCyRNA Therapeutics
86%

Trace Neuroscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 12, 2024

Key People

Founding team and executive leadership

Megan Baierlein

Chief Operating Officer

Executive Team

Irina Antonijevic

Chief Medical Officer

Executive Team

Trace Neuroscience Investors

Notable investors and investment history

Trace Neuroscience investors
InvestorRounds
RA Capital ManagementSeries A
GVSeries A
Atlas VentureSeries A
Third Rock VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 25, 2026

    Developing medicines to restore UNC13A gene function for nerve-muscle communication.

  • Nov 12, 2024

    $101M round led by Third Rock Ventures

Trace Neuroscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Trace Neuroscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Trace Neuroscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range20
Year Founded2024
Last FundingNov 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?